...co-stimulatory checkpoint OX40L for inflammatory indications. Its other clinical program also targets a co-stimulatory checkpoint, ICOS...

...which it designs antibodies from transgenic mice. Behind it in the clinic is KY1044, an ICOS-targeting...
...with PD-L1 inhibitor Tecentriq atezolizumab to treat a basket of solid-tumor cancers.Although Sturge acknowledged that ICOS...

...checkpoints. Its most advanced next generation checkpoint therapy, ICOS...

...Lauren Martz, Senior Editor Jounce’s strategy to re-focus its anti-ICOS mAb program on patients with ICOS-high...
...for continued enrollment.Jounce switched gears to focus on tumor-agnostic development based on biomarkers related to ICOS...
...ICOS are in clinical development. Industry will get a more complete picture of the potential for ICOS...

...modelling acute myeloid leukemia that had been given human peripheral blood mononuclear cells. The dual, inducible ICOS/CD28...
...Inc. Nordic Nanovector ASA Molecular Partners AG Inducible T cell co-stimulator ligand (ICOSLG) (B7-H2) (B7RP1) CD28 Inducible T cell co-stimulator (ICOS) CC...

...near-term expenditures are associated with its lead program, anti-ICOS...
...second-line NSCLC patients.Some doubts had arisen about ICOS’s...

...exclusive, worldwide option to license ALPN-101, an Fc fusion protein dual antagonist of CD28 and ICOS...
...Remy Durand, Alpine’s SVP of BD and corporate strategy, told BioCentury that ALPN-101’s dual CD28/ICOS...
...a key co-stimulatory receptor on naïve T cells. Once differentiated into effector T cells, however, ICOS...

...no approved PD-1 inhibitors. An example of the first arm of the strategy is GSK’s ICOS...
...Epidermal growth factor receptor HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 ICOS...

...also make an appearance at the meeting. GSK will present an updated analysis of its ICOS...
...Epidermal growth factor receptor 2 HER3 (ERBB3; EGFR3) - Erb-b2 receptor tyrosine kinase 3 ICOS...

...but was able to reintroduce it to patients at a lower dose. The immunostimulatory receptor ICOS...